Xu CR - Search Results

1

First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial.

Liu SM, Tu HY, Wei XW, Yan HH, Dong XR, Cui JW, Zhou Z, Xu CR, Zheng MY, Li YS, Wang Z, Bai XY, Li AN, Sun YL, Huang J, Lin JX, Ke EE, Xu BF, Lu C, Du Y, Chen Y, Ma R, Wang BH, Cang SD, Wang BC, Chen HJ, Yang JJ, Li Y, Zhou Q, Wu YL. Liu SM, et al. Among authors: xu cr, xu bf. Nat Med. 2023 Aug;29(8):2079-2086. doi: 10.1038/s41591-023-02461-x. Epub 2023 Jul 24. Nat Med. 2023. PMID: 37488286 Clinical Trial.

2

[Relationship of the curative effects of gefitinib on non-small cell lung carcinoma to gender and to epithelial growth factor receptor status].

Xu CR, Lin JY, Wang Z, Zhou Q, Zhang GC, Wang K, Yang XN, Chen G, Yang JJ, Huang YJ, Liao RQ, Wu YL. Xu CR, et al. Zhonghua Yi Xue Za Zhi. 2006 Oct 10;86(37):2606-10. Zhonghua Yi Xue Za Zhi. 2006. PMID: 17198584 Chinese.

3

[Gefitinib target treatment in non-small cell lung cancer].

Wu YL, Yang JJ, Lin JY, Huang YJ, Liao RQ, Huang YS, Zhou Q, Xu CR, Wang Z. Wu YL, et al. Among authors: xu cr. Zhonghua Jie He He Hu Xi Za Zhi. 2007 Feb;30(2):98-102. Zhonghua Jie He He Hu Xi Za Zhi. 2007. PMID: 17445469 Clinical Trial. Chinese.

4

Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China.

Wu YL, Zhong WZ, Li LY, Zhang XT, Zhang L, Zhou CC, Liu W, Jiang B, Mu XL, Lin JY, Zhou Q, Xu CR, Wang Z, Zhang GC, Mok T. Wu YL, et al. Among authors: xu cr. J Thorac Oncol. 2007 May;2(5):430-9. doi: 10.1097/01.JTO.0000268677.87496.4c. J Thorac Oncol. 2007. PMID: 17473659 Free article.

5

[Association of XAGE-1b gene expression with clinical characteristics of non-small cell lung cancer].

Zhou Q, Guo AL, An SJ, Xu CR, Yang SQ, Wu YL. Zhou Q, et al. Among authors: xu cr. Nan Fang Yi Ke Da Xue Xue Bao. 2007 Jul;27(7):966-8. Nan Fang Yi Ke Da Xue Xue Bao. 2007. PMID: 17666327 Chinese.

6

EGFR/KRAS mutations and gefitinib therapy in Chinese NSCLC patients.

Wang Z, Wu YL, Zhang GC, Zhou Q, Xu CR, Guo AL. Wang Z, et al. Among authors: xu cr. Onkologie. 2008 Apr;31(4):174-8. doi: 10.1159/000116736. Epub 2008 Mar 20. Onkologie. 2008. PMID: 18418018

7

An autologous therapeutic dendritic cell vaccine transfected with total lung carcinoma RNA stimulates cytotoxic T lymphocyte responses against non-small cell lung cancer.

Wang K, Zhou Q, Guo AL, Xu CR, An SJ, Wu YL. Wang K, et al. Among authors: xu cr. Immunol Invest. 2009;38(7):665-80. doi: 10.1080/08820130903070528. Immunol Invest. 2009. PMID: 19811429

8

Genetic evolution of epidermal growth factor receptor in adenocarcinoma with a bronchioloalveolar carcinoma component.

Zhong WZ, Wu YL, Yang XN, Guo AL, Su J, Zhang XC, Luo DL, Wang Z, Chen HJ, Zhou Q, Xu CR, Qiao GB, Liao RQ, Yang JJ, Mok TS. Zhong WZ, et al. Among authors: xu cr. Clin Lung Cancer. 2010 May;11(3):160-8. doi: 10.3816/CLC.2010.n.020. Clin Lung Cancer. 2010. PMID: 20439191

9

[Erlotinib in the Second/Third Line Treatment of Patients with Advanced Non-small Cell Lung Cancer.].

Huang Y, Yang J, Huang Y, Xu C, Zhou Q, Wang Z, Wu Y. Huang Y, et al. Zhongguo Fei Ai Za Zhi. 2009 May 20;12(5):412-6. doi: 10.3779/j.issn.1009-3419.2009.05.019. Zhongguo Fei Ai Za Zhi. 2009. PMID: 20719136 Free article. Chinese.

10

[Optimizing the methods of whole lung cancer RNA-loaded dendritic cells].

Wang K, Wu Y, Zhou Q, Xu C, Lin J, Yang X, Huang S. Wang K, et al. Zhongguo Fei Ai Za Zhi. 2005 Dec 20;8(6):489-94. doi: 10.3779/j.issn.1009-3419.2005.06.01. Zhongguo Fei Ai Za Zhi. 2005. PMID: 21208534 Free article. Chinese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

182 results

Search Page

Filters